<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465982</url>
  </required_header>
  <id_info>
    <org_study_id>1/18</org_study_id>
    <nct_id>NCT03465982</nct_id>
  </id_info>
  <brief_title>Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer</brief_title>
  <acronym>TiMiSNaR</acronym>
  <official_title>Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multicenter, prospective, randomized controlled, unblinded, parallel-group
      trial comparing standard and delayed surgery after neoadjuvant chemoradiotherapy for the
      curative treatment of rectal cancer. Three-hundred and thirty-two patients will be randomized
      on an equal basis to either robotic-assisted/standard laparoscopic rectal cancer surgery
      after 8 weeks or robotic-assisted/standard laparoscopic rectal cancer surgery after 12 weeks.
      The recruiting interval will be of 5 years and the follow-up period will end 5 years after
      the last patient is randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE

      To demonstrate if delayed timing of surgery after neoadjuvant chemoradiotherapy actually
      affects pathological complete response (pCR) and reflects on disease-free survival (DFS) and
      overall survival (OS) rather than standard timing. Eight weeks are the current standard
      interval to surgery after neoadjuvant treatment, while 12 weeks represent the &quot;minimum&quot;
      longer time interval to determine further tumor modifications and the &quot;a priori&quot; choice to
      avoid hypothetical surgical detrimental effect (postoperative complications related to
      radiation therapy).

      Primary Endpoint

        -  pCR

      Secondary Endpoints

        -  DFS

        -  OS

        -  QoL (quality of Life)

      Site Eligibility

      The trial is a multicenter collaboration, involving all those centers able to provide the
      standard of cure for locally advanced rectal cancer. All the involved centers have to respect
      the following criteria:

        -  Site able to perform robotic-assisted and standard laparoscopic rectal cancer surgery
           and TaTME (transanal total mesorectal excision)

        -  Site able to provide a preoperative work up according to the work up criteria specified
           in this trial

        -  Site able to provide standard neoadjuvant treatment, both chemo and radiation therapy,
           according to the criteria specified in this trial

        -  Predicted capability to recruit a minimum of 15 patients per year to the trial.

      Randomization will take place after consent is obtained and after patients have completed
      their baseline patient reported questionnaires. Patient consent and randomization will take
      place as close to the date of start of the neoadjuvant treatment as possible and must be no
      more than 30 days prior to planned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response (pCR)</measure>
    <time_frame>8-12 weeks</time_frame>
    <description>Pathologic Complete response on cancer defined as absence of cancer cells on specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>5 years</time_frame>
    <description>Disease Free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Interval Time Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimally invasive surgery after 8 weeks from chemoradiation treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Interval Time Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimally invasive surgery after 12 weeks from chemoradiation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery after 8 weeks from chemoradiation treatment</intervention_name>
    <description>Minimally invasive surgery after 8 weeks from chemoradiation treatment</description>
    <arm_group_label>Standard Interval Time Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery after 12 weeks from chemoradiation treatment</intervention_name>
    <description>Minimally invasive surgery after 12 weeks from chemoradiation treatment</description>
    <arm_group_label>Delayed Interval Time Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  cT3/4N0/+M0 confirmed on CT-scan, MRI (stratification for T3a-b-c-d) 3

          -  Tumor starting from the distal or medium rectum (even those crossing the peritoneal
             reflection at distal margin, within 15 cm from the anal margin)

          -  Histologically-proven adenocarcinoma of the rectum

          -  Eligible for a resective surgery with TME (low anterior resection, intersphincteric
             resection, abdominoperineal resection)

          -  Eligible for resection by minimally-invasive surgery (standard or robotic-assisted
             laparoscopic procedure, all robotic systems will be accepted)

          -  Eligible for chemoradiation treatment

          -  Able to give written informed consent

          -  Capable of completing required questionnaires at time of consent (provided
             questionnaires are available in a language spoke fluently by the participant)

        Exclusion Criteria:

          -  Metastatic disease

          -  Squamous carcinoma of the anal canal

          -  Synchronous colorectal tumors requiring multi-segment surgical resection (n.b. a
             benign lesion within the resection field in addition to the main cancer would not
             exclude a patient)

          -  History of psychiatric or addictive disorder or other medical condition that, in the
             opinion of the investigator, would preclude the patient from meeting the trial
             requirements

          -  Pregnancy

          -  Unable to complete neoadjuvant treatment

          -  Unable to give free informed consent

          -  Previous radiation treatment on the pelvis

          -  Inflammatory bowel disease

          -  Hereditary colorectal disease

          -  Previous tumors other than non-melanoma skin cancer, papillary or follicular thyroid
             cancer

          -  Participation in another rectal cancer clinical trial relating to the topic of this
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Igor Monsellato, MD</last_name>
    <phone>+390131206506</phone>
    <email>igor.monsellato@ospedale.al.it</email>
  </overall_contact>
  <results_reference>
    <citation>Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.</citation>
    <PMID>15496622</PMID>
  </results_reference>
  <results_reference>
    <citation>Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. Ann Surg. 2016 Mar;263(3):458-64. doi: 10.1097/SLA.0000000000000368.</citation>
    <PMID>24263329</PMID>
  </results_reference>
  <results_reference>
    <citation>Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, Syk I, Glimelius B, Martling A. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017 Mar;18(3):336-346. doi: 10.1016/S1470-2045(17)30086-4. Epub 2017 Feb 10.</citation>
    <PMID>28190762</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaytan-Saglam E, Balik E, Saglam S, Akgün Z, Ibis K, Keskin M, Dagoglu N, Kapran Y, Gulluoglu M. Delayed versus immediate surgery following short-course neoadjuvant radiotherapy in resectable (T3N0/N+) rectal cancer. J Cancer Res Clin Oncol. 2017 Aug;143(8):1597-1603. doi: 10.1007/s00432-017-2406-6. Epub 2017 Apr 3.</citation>
    <PMID>28374169</PMID>
  </results_reference>
  <results_reference>
    <citation>Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol. 2016 Nov 1;34(31):3773-3780. doi: 10.1200/JCO.2016.67.6049.</citation>
    <PMID>27432930</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria</investigator_affiliation>
    <investigator_full_name>Igor Monsellato</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>robotic rectal cancer resection</keyword>
  <keyword>minimally invasive surgery</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>chemoradiation treatment rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

